Kyle Doherty

Matthew Hadfield, DO, discusses how hematology/oncology fellows should approach the interpretation of clinical trial data.

Neoadjuvant vidutolimod plus pembrolizumab showed promising activity in stage III resectable melanoma.

Sigvotatug vedotin is being compared with docetaxel in patients with pretreated NSCLC in the phase 3 Be6A Lung-01 study.

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

Dalpiciclib plus pyrotinib and endocrine therapy was active with a manageable safety profile in patients with ER-positive, HER2-positive advanced breast cancer.

The FDA has cleared iPETcertum for PET and PET-CT/MRI scan enhancement in patients with cancer and suspicious lesions.

Fulzerasib monotherapy was safe and active in KRAS G12C–mutated metastatic colorectal cancer.

China’s NMPA has accepted the sNDA for first-line toripalimab plus disitamab vedotin in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Timothy Gershon, MD, PhD, discusses how the FDA approval of mirdametinib will affect the treatment paradigm for adult patients with NF1-associated PNs.

Epcoritamab plus rituximab and lenalidomide met the dual primary end points of the EPCORE FL-1 in relapsed/refractory follicular lymphoma.

The FDA accepted the NDA seeking the approval of a new formulation of piflufolastat F 18 in prostate cancer.

The phase 1/2 CaRe Prostate trial examining INKmune in patients with metastatic CRPC has met its primary and secondary end points.

Rana R. McKay, MD, FASCO, discusses findings from the ARC-20 trial of casdatifan plus cabozantinib in pretreated clear cell renal cell carcinoma.

Health Canada has expanded the approval of asciminib to include newly diagnosed and pretreated Ph-positive CML.

Jorge J. Nieva, MD, compares treatment options for patients with ROS1-positive non–small cell lung cancer.

Hossein Borghaei, DO, MS, discusses novel approaches to overcoming immunotherapy resistance in patients with non–small cell lung cancer.

Marina C. Garassino, MD, discusses the standing of durvalumab and other immunotherapy-based approaches in locally advanced NSCLC.

Lyudmila A. Bazhenova, MD, discusses considerations for treatment intensification in patients with EGFR-mutated NSCLC.

OncLive spoke with experts working to develop cellular therapies in solid tumors to gain insights into their current standing and future in the space.

PF-07248144 is a first-in-class selective inhibitor of KAT6A and KAT6B that has displayed the ability to suppress ER expression in a preclinical study.

KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.

Luspatercept plus a concomitant JAK inhibitor didn’t meet the primary end point of 12-week RBC transfusion independence in myelofibrosis-associated anemia.

Sandip P. Patel, MD, discusses targeted therapy combination regimens in EGFR-mutated NSCLC.

Nimotuzumab plus chemotherapy was more effective than chemotherapy alone in patients with recurrent or persistent cervical cancer.

STAR-221 will evaluate domvanalimab plus zimberelimab and chemotherapy for the first-line treatment of patients with gastric, GEJ, or esophageal adenocarcinoma.

The combination of sarilumab, ipilimumab, nivolumab, and relatlimab displayed activity in patients with stage III or IV melanoma.

In an OncLive Peer Exchange filmed during EBMT, investigators discuss approaches to optimizing allo-HSCT and preventing GVHD in hematologic malignancies.

The FDA has received an NDA for relacorilant for the treatment of patients with platinum-resistant ovarian cancer.

Regorafenib plus trifluridine/tipiracil was active in patients with pretreated metastatic colorectal cancer.

The NMPA has approved lisaftoclax in adult patients with relapsed/refractory CLL/SLL.